.Attribute Medication, Posted online: 13 September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized phase 3b/4 DESTINY-Breast12 study, trastuzumab deruxtecan (T-DXd) therapy of individuals with HER2+ innovative bosom cancer cells and also active or stable mind metastases revealed regular intracranial task and also wide spread efficiency of T-DXd.